Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 03:03PM ET
77.44
Dollar change
-1.12
Percentage change
-1.43
%
Index- P/E26.61 EPS (ttm)2.91 Insider Own35.15% Shs Outstand145.16M Perf Week-11.58%
Market Cap10.66B Forward P/E22.84 EPS next Y3.39 Insider Trans-0.12% Shs Float89.28M Perf Month-16.70%
Income427.20M PEG1.88 EPS next Q0.47 Inst Own83.03% Short Float3.72% Perf Quarter7.65%
Sales2.96B P/S3.60 EPS this Y5.09% Inst Trans-11.09% Short Ratio4.14 Perf Half Y28.70%
Book/sh9.49 P/B8.16 EPS next Y25.06% ROA10.87% Short Interest3.32M Perf Year-6.53%
Cash/sh3.55 P/C21.83 EPS next 5Y14.15% ROE34.30% 52W Range53.79 - 94.86 Perf YTD5.39%
Dividend Est.0.20 (0.26%) P/FCF43.84 EPS past 5Y20.48% ROI16.35% 52W High-18.36% Beta1.22
Dividend TTM0.20 (0.26%) Quick Ratio0.99 Sales past 5Y9.74% Gross Margin51.17% 52W Low43.97% ATR (14)2.35
Dividend Ex-DateFeb 29, 2024 Current Ratio1.80 EPS Y/Y TTM46.17% Oper. Margin16.27% RSI (14)22.29 Volatility3.46% 2.25%
Employees9707 Debt/Eq1.00 Sales Y/Y TTM17.14% Profit Margin14.41% Recom2.00 Target Price86.90
Option/ShortYes / Yes LT Debt/Eq0.90 EPS Q/Q113.71% Payout6.89% Rel Volume0.90 Prev Close78.56
Sales Surprise5.83% EPS Surprise2.44% Sales Q/Q20.62% EarningsFeb 13 BMO Avg Volume801.85K Price77.44
SMA20-13.68% SMA50-10.94% SMA2007.99% Trades Volume622,184 Change-1.43%
Date Action Analyst Rating Change Price Target Change
Feb-14-24Upgrade JP Morgan Neutral → Overweight $60 → $90
Dec-19-23Initiated Wells Fargo Equal Weight $72
Dec-13-23Initiated Wolfe Research Outperform $80
Oct-21-22Initiated UBS Buy $70
Aug-22-22Upgrade Citigroup Neutral → Buy $70 → $80
Oct-15-21Resumed Cowen Market Perform $68
Jun-15-21Upgrade Cleveland Research Neutral → Buy
Feb-05-21Downgrade Wells Fargo Overweight → Equal Weight $50 → $55
Dec-02-20Initiated Goldman Sell $50
Nov-16-20Upgrade Wolfe Research Underperform → Peer Perform
Apr-18-24 06:46AM
Apr-09-24 09:02AM
Apr-08-24 07:00AM
07:00AM
Apr-04-24 08:11AM
07:00AM Loading…
Apr-01-24 07:00AM
Mar-22-24 09:48AM
Mar-14-24 11:30AM
09:08AM
Mar-12-24 07:51AM
Mar-11-24 07:00AM
Mar-07-24 07:00AM
Mar-06-24 05:01PM
Mar-05-24 08:23AM
Mar-01-24 08:39AM
07:00AM Loading…
Feb-28-24 07:00AM
Feb-26-24 05:00PM
05:00PM
10:52AM
10:42AM
09:37AM
Feb-17-24 02:00PM
Feb-16-24 04:05PM
Feb-15-24 09:07AM
Feb-14-24 10:03AM
02:06AM
Feb-13-24 09:30AM
08:45AM
07:51AM
07:49AM
07:00AM Loading…
07:00AM
Feb-12-24 12:10PM
09:14AM
Feb-07-24 07:00AM
Feb-06-24 04:05PM
07:00AM
Feb-05-24 07:00AM
Feb-01-24 10:00AM
Jan-30-24 01:36PM
Jan-29-24 10:41AM
Jan-25-24 07:00AM
Jan-23-24 08:00AM
Jan-16-24 11:22AM
Jan-11-24 12:10PM
Jan-05-24 08:05AM
Jan-04-24 08:00AM
08:00AM
Jan-03-24 04:35PM
07:00AM
Dec-27-23 07:34AM
Dec-20-23 11:32AM
Dec-19-23 09:41AM
Nov-28-23 07:50AM
Nov-27-23 09:15AM
Nov-20-23 04:15PM
Nov-07-23 09:00AM
Nov-06-23 07:18AM
Nov-04-23 01:25PM
Nov-02-23 09:18AM
07:33AM
07:00AM
Oct-27-23 11:07AM
Oct-26-23 10:02AM
Oct-20-23 12:10PM
Oct-12-23 08:13AM
Oct-05-23 08:32AM
Oct-04-23 08:47AM
07:00AM
Oct-03-23 07:00AM
Oct-02-23 04:05PM
Sep-19-23 01:09PM
Sep-18-23 07:00AM
Sep-15-23 04:06AM
Sep-12-23 11:48AM
Sep-08-23 07:54AM
Sep-07-23 07:00AM
Sep-06-23 07:43AM
Sep-05-23 04:02PM
Aug-24-23 04:05PM
06:21AM
Aug-18-23 11:09AM
Aug-17-23 09:00AM
Aug-16-23 04:05PM
Aug-14-23 07:00AM
Aug-13-23 09:35AM
Aug-04-23 09:45AM
12:51AM
Aug-03-23 11:40PM
11:30AM
08:35AM
07:24AM
07:00AM
Aug-02-23 08:05AM
Jul-31-23 08:51AM
Jul-29-23 10:06AM
Jul-25-23 04:44PM
Jul-11-23 08:52AM
Jul-10-23 07:00AM
Jul-04-23 10:31AM
Jul-03-23 08:15AM
Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Gunther Laukien in 1960 and is headquartered in Billerica, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Requardt Hermann FritzDirectorMar 04 '24Option Exercise22.0515,000330,75038,147Mar 06 04:05 PM
Requardt Hermann FritzDirectorMar 04 '24Sale90.0615,0001,350,89823,147Mar 06 04:05 PM
Busse FalkoPRESIDENT, BIOSPIN GROUPFeb 28 '24Option Exercise26.2828,122739,15660,981Mar 01 04:05 PM
Busse FalkoPRESIDENT, BIOSPIN GROUPFeb 28 '24Sale85.4828,1222,403,89032,859Mar 01 04:05 PM
Prause BurkhardPRES. & CEO, BRUKER BESTFeb 22 '24Option Exercise43.175,450235,29232,384Feb 26 04:02 PM
Prause BurkhardPRES. & CEO, BRUKER BESTFeb 22 '24Sale83.3015,3191,276,07317,065Feb 26 04:02 PM
LINTON WILLIAM ADirectorDec 05 '23Option Exercise19.0710,000190,70033,048Dec 07 04:01 PM
LAUKIEN FRANK HPRESIDENT & CEOOct 26 '23Option Exercise46.1459,5232,746,68938,327,911Oct 30 04:11 PM
LAUKIEN FRANK HPRESIDENT & CEOAug 08 '23Option Exercise47.8544,1502,112,57838,255,291Aug 10 05:09 PM
LAUKIEN FRANK HPRESIDENT & CEOAug 08 '23Sale64.8137,9472,459,34538,217,344Aug 10 05:09 PM
LAUKIEN FRANK HPRESIDENT & CEOJul 27 '23Option Exercise37.4268,4542,561,54938,249,088Jul 31 04:10 PM
Herman Gerald NEXECUTIVE VICE PRESIDENT, CFOJun 16 '23Sale75.4214,2421,074,13236,462Jun 20 04:31 PM
Kastner Marc ADirectorMay 19 '23Sale75.2211,146838,4028,051May 22 04:15 PM
LAUKIEN FRANK HPRESIDENT & CEOMay 16 '23Sale73.1114,6251,069,17438,180,634May 17 04:17 PM
LAUKIEN FRANK HPRESIDENT & CEOMay 15 '23Sale72.75185,37513,485,86638,262,287May 17 04:17 PM
LAUKIEN FRANK HPRESIDENT & CEOMay 09 '23Sale75.20110,9828,345,41038,100,011May 10 04:18 PM
LAUKIEN FRANK HPRESIDENT & CEOMay 08 '23Sale77.0589,0186,859,09438,210,993May 10 04:18 PM
LAUKIEN FRANK HPRESIDENT & CEOMay 03 '23Sale79.2116,4351,301,81638,352,034May 04 04:11 PM
LAUKIEN FRANK HPRESIDENT & CEOMay 02 '23Sale77.98100,7707,858,03038,161,517May 03 04:15 PM
LAUKIEN FRANK HPRESIDENT & CEOMay 01 '23Sale78.7582,7956,519,84138,262,287May 03 04:15 PM
LAUKIEN FRANK HPRESIDENT & CEOApr 25 '23Sale78.8651,7704,082,70238,262,287Apr 26 04:17 PM
LAUKIEN FRANK HPRESIDENT & CEOApr 24 '23Sale81.02148,23012,009,46138,349,926Apr 26 04:17 PM
Last Close
Apr 19 03:03PM ET
24.86
Dollar change
+0.17
Percentage change
0.69
%
PTCT PTC Therapeutics Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-8.37 Insider Own3.79% Shs Outstand75.71M Perf Week-5.90%
Market Cap1.90B Forward P/E- EPS next Y-4.92 Insider Trans-1.33% Shs Float73.71M Perf Month-15.76%
Income-626.60M PEG- EPS next Q-1.28 Inst Own110.35% Short Float13.92% Perf Quarter-8.13%
Sales937.82M P/S2.03 EPS this Y26.53% Inst Trans1.90% Short Ratio11.27 Perf Half Y21.27%
Book/sh-10.81 P/B- EPS next Y20.02% ROA-34.73% Short Interest10.26M Perf Year-53.27%
Cash/sh11.44 P/C2.17 EPS next 5Y-9.51% ROE- 52W Range17.53 - 59.84 Perf YTD-9.80%
Dividend Est.- P/FCF- EPS past 5Y-24.94% ROI- 52W High-58.46% Beta0.71
Dividend TTM- Quick Ratio1.97 Sales past 5Y29.08% Gross Margin69.28% 52W Low41.81% ATR (14)1.35
Dividend Ex-Date- Current Ratio2.02 EPS Y/Y TTM-7.52% Oper. Margin-37.26% RSI (14)34.88 Volatility4.72% 4.77%
Employees995 Debt/Eq- Sales Y/Y TTM34.20% Profit Margin-66.81% Recom2.93 Target Price29.17
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q12.28% Payout- Rel Volume0.69 Prev Close24.69
Sales Surprise-2.51% EPS Surprise-1390.59% Sales Q/Q83.41% EarningsApr 25 AMC Avg Volume910.31K Price24.86
SMA20-9.84% SMA50-11.18% SMA200-14.68% Trades Volume543,714 Change0.69%
Date Action Analyst Rating Change Price Target Change
Dec-19-23Downgrade Morgan Stanley Equal-Weight → Underweight $28
Dec-08-23Initiated Wells Fargo Overweight $37
Oct-30-23Upgrade Oppenheimer Perform → Outperform $165
Oct-27-23Downgrade Citigroup Neutral → Sell $29 → $17
Oct-06-23Downgrade Truist Buy → Hold $45 → $25
Sep-18-23Downgrade Citigroup Buy → Neutral $55 → $28
Sep-15-23Downgrade Raymond James Outperform → Underperform
Mar-17-23Initiated SVB Securities Market Perform $48
Dec-14-22Initiated Goldman Sell $35
Sep-12-22Initiated Jefferies Buy $62
Apr-18-24 10:01AM
Apr-11-24 08:00AM
Mar-28-24 08:30AM
Mar-25-24 10:00AM
Mar-20-24 02:00PM
07:30AM Loading…
Mar-19-24 07:30AM
Mar-02-24 08:56AM
Mar-01-24 06:51AM
Feb-29-24 06:00PM
05:20PM
04:33PM
04:30PM
04:05PM
Feb-27-24 05:20PM
Feb-26-24 09:16AM
04:30PM Loading…
Feb-22-24 04:30PM
Feb-15-24 08:00AM
Feb-13-24 10:00AM
Feb-11-24 01:45AM
Jan-26-24 04:06PM
11:45AM
10:18AM
Jan-25-24 04:51PM
04:20PM
04:05PM
Jan-24-24 07:02PM
Jan-12-24 01:02AM
Jan-08-24 09:26AM
Jan-03-24 08:00AM
Dec-20-23 09:41AM
05:01PM Loading…
Dec-15-23 05:01PM
Dec-14-23 04:30PM
Dec-05-23 04:15PM
Nov-14-23 03:58PM
Nov-03-23 04:30PM
Oct-30-23 09:03AM
Oct-27-23 11:22AM
10:01AM
08:33AM
07:15AM
02:38AM
Oct-26-23 07:30PM
06:10PM
05:30PM
04:25PM
04:05PM
Oct-24-23 10:00AM
Oct-19-23 07:02PM
10:01AM
08:00AM
Oct-16-23 04:30PM
Oct-11-23 08:07AM
Oct-06-23 09:42AM
Sep-29-23 11:18AM
Sep-28-23 05:15PM
04:42PM
04:30PM
Sep-25-23 03:18AM
Sep-20-23 04:00AM
Sep-19-23 06:46AM
Sep-15-23 04:04PM
09:28AM
06:00AM
Sep-12-23 08:00AM
Sep-07-23 07:33PM
08:00AM
08:00AM
Aug-30-23 08:00AM
Aug-28-23 08:00AM
Aug-25-23 01:38PM
Aug-04-23 01:24PM
Aug-03-23 09:30PM
05:25PM
04:14PM
04:01PM
Jul-21-23 09:30AM
Jul-20-23 08:00AM
Jul-19-23 04:30PM
Jul-18-23 04:30PM
Jul-17-23 04:30PM
Jul-11-23 12:00PM
Jun-30-23 10:18AM
Jun-29-23 04:30PM
09:18AM
Jun-28-23 07:41AM
Jun-21-23 04:24PM
07:31AM
07:12AM
07:00AM
Jun-15-23 04:30PM
Jun-02-23 08:00AM
May-31-23 06:05AM
May-25-23 10:32AM
May-24-23 04:06PM
12:48PM
12:33PM
May-23-23 05:36PM
04:07PM
04:05PM
May-18-23 12:59PM
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Golden Lee ScottEVP & CHIEF MEDICAL OFFICERApr 02 '24Sale28.3752614,92359,988Apr 04 05:16 PM
Boulding Mark ElliottEXEC. VP AND CLOJan 30 '24Sale27.2579421,63771,189Feb 01 04:17 PM
Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERJan 30 '24Sale27.2561816,84161,202Feb 01 04:18 PM
Pauwels EricCHIEF BUSINESS OFFICERJan 30 '24Sale27.253669,97444,181Feb 01 04:16 PM
Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICERJan 30 '24Sale27.253188,66635,528Feb 01 04:15 PM
Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERJan 30 '24Sale27.25287633,706Feb 01 04:18 PM
Jacobson Allan StevenDirectorJan 22 '24Option Exercise27.0510,000270,50022,348Jan 24 04:30 PM
Jacobson Allan StevenDirectorJan 22 '24Sale27.3810,000273,80412,348Jan 24 04:30 PM
Klein Matthew B.CHIEF EXECUTIVE OFFICERJan 09 '24Sale29.015,443157,928160,475Jan 10 04:08 PM
Pauwels EricCHIEF BUSINESS OFFICERJan 09 '24Sale29.012,06559,91644,547Jan 10 04:09 PM
Boulding Mark ElliottEXEC. VP AND CLOJan 09 '24Sale29.011,93856,23171,983Jan 10 04:04 PM
Utter Christine MarieSVP, FINANCE & CAOJan 09 '24Sale29.011,65347,96135,846Jan 10 04:11 PM
Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERJan 09 '24Sale29.011,52144,13261,820Jan 10 04:03 PM
Golden Lee ScottCHIEF MEDICAL OFFICERJan 09 '24Sale29.011,22535,54337,914Jan 10 04:06 PM
Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERJan 09 '24Sale29.011002,9013,734Jan 10 04:03 PM
Klein Matthew B.CHIEF EXECUTIVE OFFICERJan 08 '24Sale28.642,23764,068165,918Jan 10 04:08 PM
Pauwels EricCHIEF BUSINESS OFFICERJan 08 '24Sale28.641,56944,93746,612Jan 10 04:09 PM
Boulding Mark ElliottEXEC. VP AND CLOJan 08 '24Sale28.641,45741,72973,921Jan 10 04:04 PM
SCHMERTZLER MICHAELDirectorJan 08 '24Sale27.811,50041,715115,266Jan 10 04:10 PM
Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERJan 08 '24Sale28.641,23635,39963,341Jan 10 04:03 PM
Utter Christine MarieSVP, FINANCE & CAOJan 08 '24Sale28.641,18834,02537,499Jan 10 04:11 PM
Golden Lee ScottCHIEF MEDICAL OFFICERJan 08 '24Sale28.6477522,19639,139Jan 10 04:06 PM
Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERJan 08 '24Sale28.64531,5183,834Jan 10 04:03 PM
Klein Matthew B.CHIEF EXECUTIVE OFFICERJan 05 '24Sale27.1510,107274,393168,155Jan 09 04:29 PM
Gravier PierreCHIEF FINANCIAL OFFICERDec 12 '23Buy25.817,700198,73633,700Dec 14 04:38 PM
Young AlethiaDirectorSep 06 '23Option Exercise27.8511,666324,89816,067Sep 08 04:02 PM
Young AlethiaDirectorSep 06 '23Sale39.8611,666464,9729,067Sep 08 04:02 PM
SCHMERTZLER MICHAELDirectorJun 07 '23Sale44.861,00044,860116,766Jun 09 04:03 PM
Reeve EmmaDirectorMay 23 '23Option Exercise33.382,65288,5208,602May 24 04:12 PM
Reeve EmmaDirectorMay 23 '23Sale59.532,652157,8857,200May 24 04:12 PM
Reeve EmmaDirectorMay 22 '23Option Exercise33.377,116237,48411,148May 24 04:12 PM
Reeve EmmaDirectorMay 22 '23Sale59.537,116423,6307,200May 24 04:12 PM
Pauwels EricCHIEF BUSINESS OFFICERMay 22 '23Sale59.012,013118,79147,553May 23 04:05 PM
Pauwels EricCHIEF BUSINESS OFFICERMay 19 '23Sale58.966,403377,49149,566May 23 04:05 PM
Pauwels EricCHIEF BUSINESS OFFICERMay 18 '23Sale58.7178846,26755,969May 19 04:04 PM
Pauwels EricCHIEF BUSINESS OFFICERMay 17 '23Sale58.508,048470,82256,757May 19 04:04 PM
Jacobson Allan StevenDirectorMay 11 '23Option Exercise10.8523,000249,55035,348May 12 04:08 PM
Jacobson Allan StevenDirectorMay 11 '23Sale55.0823,0001,266,93012,348May 12 04:08 PM
Utter Christine MarieSVP, FINANCE & CAOApr 21 '23Option Exercise33.024,692154,93042,380Apr 25 04:09 PM
Utter Christine MarieSVP, FINANCE & CAOApr 21 '23Sale55.064,692258,32638,059Apr 25 04:09 PM
Reeve EmmaDirectorApr 21 '23Sale55.054,328238,2587,200Apr 25 04:08 PM